Part 1: Exercise Mimetics 101: Why ERRs Matter for Metabolic Health
Part 2: SLU‑PP‑332: An ERR that Reprograms Muscle Fuel Use
Part 3: SLU‑PP‑332: Safety, Caveats, and Comparators
Abstract:
Early animal data in demographics that struggle with obesity, metabolic syndrome, muscle loss conditions, and selected heart‑failure support testing ERR‑agonist exercise mimetics like SLU‑PP‑332. A combination therapy with AO‑1 agents, such as AO-1SG, AO-2TZ, and AO-3RT, could offer a much-needed approach. This is for managing these conditions. The first human studies must prioritize safety and pharmacokinetics. This is necessary to support future studies into ERR‑agonist exercise mimetics like SLU‑PP‑332.
Most plausible early indications
-
Obesity with metabolic syndrome (cluster of high blood sugar, dyslipidemia, hypertension, central adiposity): Mechanistic rationale via increased resting energy expenditure and a fuel switch toward fat. Preclinical studies show ERR‑agonist exercise mimetics like SLU‑PP‑332 caused less fat mass gain, or increased fat mass loss, without inducing appetite suppression.
-
Sarcopenia (age‑related or disease‑related muscle loss): SLU‑PP‑332 ERR‑PGC‑1α signaling supports an oxidative, fatigue‑resistant muscle phenotype. The potential use case for SLU‑PP‑332 is preserving muscle when resistance exercise is not feasible or extremely limited.
-
Heart failure subsets: In energy‑starved myocardium, boosting oxidative metabolism via ERRs such as the ERR‑agonist exercise mimetics like SLU‑PP‑332, improved function in mouse models; human translation would need tight cardiac monitoring and exclusion criteria to avoid maladaptive hypertrophy.
Combining ERR‑agonist exercise mimetics like SLU‑PP‑332 with a AO‑1 receptor agonist to pair appetite‑driven weight loss with muscle preservation is an appealing hypothesis warranting controlled testing.
A realistic first‑in‑human (FIH) roadmap
-
Phase I (healthy volunteers): single‑ and multiple‑ascending‑dose cohorts; dense PK sampling; safety labs (including ALT/AST), ECGs, echocardiography (LV mass, function), and exploratory metabolic biomarkers (fasting RER via indirect calorimetry, acyl‑carnitines).
-
Phase Ib/IIa (targeted patients): short‑course randomized trials in obesity/metabolic syndrome or sarcopenia with endpoints such as DXA lean mass, resting energy expenditure, RER, VO₂peak, liver fat (MRI‑PDFF), and glycemic metrics.
-
Cardiac Sub-study: prospective imaging (echo or CMR) in any cardiometabolic cohort; if testing HF patients, enroll defined phenotypes (e.g., pressure overload vs. ischemic) and pre‑specify hypertrophy/fibrosis endpoints.
Ethics & compliance reminder:
No human efficacy claims exist yet. Translation must follow FDA/EMA pathways. Athletic use is inappropriate and could raise anti‑doping concerns. This depends on final classification for ERR‑agonist exercise mimetics like SLU‑PP‑332.
References & further reading
-
Billon et al. ACS Chemical Biology (2023): SLU‑PP‑332 induces an ERRα‑dependent acute aerobic program and boosts endurance in mice.
-
Billon et al. J Pharmacol Exp Ther (2024): In metabolic‑syndrome models, SLU‑PP‑332 shifts fuel use to fat, increases energy expenditure, reduces fat mass gain, and improves glucose tolerance (context‑dependent).
-
Xu et al. Circulation (2024): Pan‑ERR agonists ameliorated heart failure in mice by enhancing cardiac fatty‑acid metabolism and mitochondrial function.
-
Kwon et al. (2013): ERRγ–GATA4 pathway can drive cardiac hypertrophy—a key safety consideration for non‑selective agonists.
-
UF News (2023) and ACS Press (2024) for accessible summaries and context.
Works cited
https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/
https://pubmed.ncbi.nlm.nih.gov/24083978/
https://news.ufl.edu/2023/09/exercise-mimicking-drug/
https://pubmed.ncbi.nlm.nih.gov/37961903/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11584170/
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00206/full
“For education only; not medical advice; SLU‑PP‑332 is an investigational research compound with no human approval.”